Kura Oncology-backed Caspian advances KO-7246 toward Phase 1 diabetes proof-of-concept study

By Public Technologies
  • Kura Oncology outlined a development plan for KO-7246, an oral menin inhibitor for diabetes, with an investor webcast scheduled for today.
  • Preclinical findings were already presented at the EASD meeting, supporting a move toward clinical proof of concept.
  • Animal studies showed improved glucose control with signs of restored insulin-producing capacity, including effects that persisted after dosing stopped.
  • Human islet testing indicated selective expansion of insulin-producing cells, supporting the therapeutic rationale for diabetes.
  • IND-enabling work is underway for a Phase 1 study to assess safety and look for evidence of increased endogenous insulin production.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130730PRIMZONEFULLFEED9844315) on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.